Cancer Immunotherapy
Publications not from the Hospital del Mar Research Institute (HMRIB)
- Falgàs A, Lázaro-Gorines R, Zanetti SR, Rubio-Pérez L, Martinez-Moreno A, Vinyoles M, Guerrero-Murillo M, Fernandez-Fuentes N, Roca-Ho H, Tirado N, Panisello C, Velasco-Hernandez T, Mayado A, Pérez-Pons A, Genesca E, Ribera JM, Ribera J, Camos M, Ramírez-Orellana M, Anguita E, Ballerini P, Fuster JL, Juan M, González-Navarro EAA, Locatelli F, Stam RWW, Querol S, Velasco P, Ortiz-Maldonado V, Martínez-Cibrian N, Delgado J, Orfao A, Alvarez-Vallina L, Bueno C, Menendez P (2025). A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.. Blood 145, 2599-2613. Publicación CNIO.
- Velasco-Sidro M, Arroyo-Ródenas J, Díez-Alonso L, Ramírez-Fernández Á, Álvarez-Vallina L. (2025). Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers. Oncoimmunology 14, 2444701. Publicación CNIO.
- Hangiu O, Navarro R, Frago S, Rubio-Pérez L, Tapia-Galisteo A, Díez-Alonso L, Gómez-Rosel M, Silva-Pilipich N, Vanrell L, Smerdou C, Howard KA, Sanz L, Álvarez-Vallina L, Compte M. (2025). Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation. Front Inmmunol 15, 1494206. Publicación CNIO.
- Pilati D, Agyei EK, Elkhashab M, Fuchs E, Nielsen IH, Bjerg TW, Anthi AK, Jiménez-Reinoso A, Iversen MB, Pohl L, Narita R, Frago S, Jakobsen MR, Andersen JT, Degn SE, Paludan SR, Alvarez-Vallina L, Howard KA. (2025). Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction. J Biol Chem 301, 108508. Publicación CNIO.
- Díez-Alonso L, Falgas A, Arroyo-Ródenas J, Romencín PA, Martínez A, Gómez-Rosel M, Blanco B, Jiménez-Reinoso A, Mayado A, Pérez-Pons A, Aguilar-Sopeña Ó, Ramírez-Fernández Á, Segura-Tudela A, Perez-Amill L, Tapia-Galisteo A, Domínguez-Alonso C, Rubio-Pérez L, Jara M, Solé F, Hangiu O, Almagro L, Albitre Á, Penela P, Sanz L, Anguita E, Valeri A, García-Ortiz A, Río P, Juan M, Martínez-López J, Roda-Navarro P, Martín-Antonio B, Orfao A, Menéndez P, Bueno C, Álvarez-Vallina L. (2024). Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo. Sci Transl Med 16, adg7962. Publicación CNIO.
Open Access
- Jiménez-Reinoso A, Molero-Abraham M, Cirauqui C, Blanco B, Garrido-Martin EM, Nehme-Álvarez D, Domínguez-Alonso C, Ramírez-Fernández Á, Díez-Alonso L, Nuñez-Buiza Á, González-Murillo Á, Tobes R, Pareja E, Ramírez-Orellana M, Rodriguez-Peralto JL, Ferrer I, Zugazagoitia J, Paz-Ares L, Álvarez-Vallina L. (2024). CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts.. Oncoimmunology 13, 2392897. Publicación CNIO.
- Tapia-Galisteo A, Sánchez-Rodríguez I, Narbona J, Iglesias-Hernández P, Aragón-García S, Jiménez-Reinoso A, Compte M, Khan S, Tsuda T, Chames P, Lacadena J, Álvarez-Vallina L, Sanz L. (2024). Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses. Oncoimmunology 13, 2338558. Publicación CNIO.
- Navarro R, Frago S, Hangiu O, Erce-Llamazares A, Lázaro-Gorines R, Morcillo MA, Rodriguez-Peralto JL, Sanz L, Compte M, Alvarez-Vallina L. (2024). Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates. Toxicol Appl Pharm 487, 116961. Publicación CNIO.
- Rubio-Pérez L, Frago S, Compte M, Navarro R, Harwood SL, Lázaro-Gorines R, Gómez-Rosel M, Hangiu O, Silva-Pilipich N, Vanrell L, Smerdou C, Álvarez-Vallina L (2024). Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity. Antibodies 13, 34. Publicación CNIO.
- Tapia-Galisteo A, Compte M, Álvarez-Vallina L, Sanz L. (2023). When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.. Theranostics 13, 1028-1041. Publicación CNIO.
- Tapia-Galisteo A, Álvarez-Vallina L, Sanz L (2023). Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol 16, 83. Publicación CNIO.
- Rubio-Pérez L, Lázaro-Gorines R, Harwood SL, Compte M, Navarro R, Tapia-Galisteo A, Bonet J, Blanco B, Lykkemark S, Ramírez-Fernández Á, Ferreras-Gutiérrez M, Domínguez-Alonso C, Díez-Alonso L, Segura-Tudela A, Hangiu O, Erce-Llamazares A, Blanco FJ, Santos C, Rodríguez-Peralto JL, Sanz L, Álvarez-Vallina L (2023). A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.. Oncoimmunology 12, 2205336. Publicación CNIO.
- Lázaro-Gorines R, Pérez P, Heras-Murillo I, Adán-Barrientos I, Albericio G, Astorgano D, Flores S, Luczkowiak J, Labiod N, Harwood SL, Segura-Tudela A, Rubio-Pérez L, Nugraha Y, Shang X, Li Y, Alfonso C, Adipietro KA, Abeyawardhane DL, Navarro R, Compte M, Yu W, MacKerell AD Jr, Sanz L, Weber DJ, Blanco FJ, Esteban M, Pozharski E, Godoy-Ruiz R, Muñoz IG, Delgado R, Sancho D, García-Arriaza J, Álvarez-Vallina L. (2023). Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.. Adv Sci 10, e2304818. Publicación CNIO.
- Blanco B, Ramírez-Fernández A, Bueno C, Argemí-Muntadas A, Fuentes P, Aguilar-Sopeña O, Gutierrez-Agüera F, Romina Zanetti S, Tapia-Galisteo A, Díez-Alonso L, Segura-Tudela A, Castellà M, Marzal B, Betriu S, Harwood SL, Compte C, Lykkemark S, Erce-Llamazares A, Rubio-Pérez L, Jiménez-Reinoso A, Domínguez-Alonso C, Neves M, Morales P, Paz-Artal E, Guedan S, Sanz L, Toribio ML, Roda-Navarro P, Juan M, Menéndez P, Álvarez-Vallina L (2022). Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T cell engagers.. Cancer Immunol Res 10, 498-511. Publicación en otras instituciones.
- Jiménez-Reinoso A, Tirado N, Martinez-Moreno A, Diaz VM, García-Peydró M, Hangiu O, Diez-Alonso L, Albitre A, Penela P, Toribio ML, Menendez P, Alvarez-Vallina L, Sanchez Martinez D. (2022). Efficient treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.. J Immunother Cancer 10, e005333. Publicación CNIO. Open Access
- Ramírez-Fernández A, Aguilar-Sopeña O, Díez-Alonso L, Segura-Tudela A, Domínguez-Alonso C, Álvarez-Vallina L, Blanco B (2022). Synapse topology and downmodulation events are determinant for the functional outcome of anti-CD19 T cell-redirecting strategies.. Oncoimmunology 11, 2054106. Publicación en otras instituciones.
- Tapia-Galisteo A, Sánchez-Rodríguez I, Aguilar-Sopeña O, Harwood SL, Navarro R, Martín-García L, Gutiérrez F, Corbacho C, Compte M, Blanco FJ, Chames P, Roda-Navarro P, Álvarez-Vallina L, Sanz L (2022). Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. Oncoimmunology 11, 2034355. Publicación en otras instituciones.
- Rousso-Noori L, Mastandrea I, Talmor S, Waks T, Globerson Levin A, Haugas M, Teesalu T, Alvarez-Vallina L, Eshhar Z, Friedmann-Morvinski D (2021). P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas.. Nat Commun 12, 3615. Publicación en otras instituciones. Open Access
- Blanco B, Domínguez-Alonso C, Alvarez-Vallina L. (2021). Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.. Clin Cancer Res 27, 5457-5464. Publicación en otras instituciones.
- Compte M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, Romero E, Ferrer I, Garrido-Martin EM, Enguita AB, Ochoa MC, Blanco B, Oteo M, Merino N, Nehme-Álvarez D, Hangiu O, Domínguez-Alonso C, Zonca M, Ramírez-Fernández A, Blanco FJ, Morcillo MA, Muñoz IG, Melero I, Rodriguez-Peralto JL, Paz-Ares L, Sanz L, Alvarez-Vallina L. (2021). An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity. Clin Cancer Res 27, 3167-3177. Publicación CNIO.
- Jiménez-Reinoso A, Nehme-Álvarez D, Domínguez-Alonso C, Álvarez-Vallina L. (2021). Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential.. Front Oncol 10, 593848. Publicación en otras instituciones.
- Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, Dagnæs-Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA. (2021). Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Commun Biol 4, 310. Publicación en otras instituciones.
